PHO Stock Overview
Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PHO from our risk checks.
Photocure ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr60.00 |
| 52 Week High | kr71.90 |
| 52 Week Low | kr40.70 |
| Beta | 0.89 |
| 1 Month Change | 9.49% |
| 3 Month Change | 0.33% |
| 1 Year Change | 12.15% |
| 3 Year Change | -56.62% |
| 5 Year Change | 22.95% |
| Change since IPO | -68.09% |
Recent News & Updates
Recent updates
Photocure ASA's (OB:PHO) 26% Jump Shows Its Popularity With Investors
Dec 18
Potential Upside For Photocure ASA (OB:PHO) Not Without Risk
Sep 01Time To Worry? Analysts Just Downgraded Their Photocure ASA (OB:PHO) Outlook
Mar 01Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report
Aug 14We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt
Aug 12Do Institutions Own Photocure ASA (OB:PHO) Shares?
Feb 11Photocure ASA's (OB:PHO) Stock Is Going Strong: Have Financials A Role To Play?
Jan 21The Photocure (OB:PHO) Share Price Is Up 286% And Shareholders Are Boasting About It
Dec 31
We're Not So Sure You Should Rely on Photocure's (OB:PHO) Statutory Earnings
Dec 09Is Photocure (OB:PHO) Using Too Much Debt?
Nov 19Shareholder Returns
| PHO | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | 3.8% | 0.3% | -1.0% |
| 1Y | 12.1% | 10.5% | 7.1% |
Return vs Industry: PHO exceeded the Norwegian Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: PHO exceeded the Norwegian Market which returned 7.1% over the past year.
Price Volatility
| PHO volatility | |
|---|---|
| PHO Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.5% |
| 10% least volatile stocks in NO Market | 3.0% |
Stable Share Price: PHO has not had significant price volatility in the past 3 months.
Volatility Over Time: PHO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 102 | Dan Schneider | www.photocure.com |
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
Photocure ASA Fundamentals Summary
| PHO fundamental statistics | |
|---|---|
| Market cap | kr1.63b |
| Earnings (TTM) | kr4.82m |
| Revenue (TTM) | kr512.45m |
337.3x
P/E Ratio3.2x
P/S RatioIs PHO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHO income statement (TTM) | |
|---|---|
| Revenue | kr512.45m |
| Cost of Revenue | kr27.40m |
| Gross Profit | kr485.05m |
| Other Expenses | kr480.23m |
| Earnings | kr4.82m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 94.65% |
| Net Profit Margin | 0.94% |
| Debt/Equity Ratio | 0% |
How did PHO perform over the long term?
See historical performance and comparison